SEC Comment Letter for Tonix Pharmaceuticals Holding Corp. (TNXP) (CIK 0001430306) (TNXP) — Jun 24, 2019
Tonix Pharmaceuticals Holding Corp. (TNXP) (CIK 0001430306)
Date: June 24, 2019 · CIK: 0001430306 · Accession: 0000000000-19-010237
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-232195
Letter
June 24, 2019 Seth Lederman Chief Executive Officer Tonix Pharmaceuticals Holding Corp. 509 Madison Avenue, Suite 1608 New York, NY 10022 Re:Tonix Pharmaceuticals Holding Corp. Registration Statement on Form S-1 Filed June 19, 2019 File No. 333-232195 Dear Mr. Lederman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Sonia Bednarowski at 202-551-3666 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance
Show Raw Text
June 24, 2019
Seth Lederman
Chief Executive Officer
Tonix Pharmaceuticals Holding Corp.
509 Madison Avenue, Suite 1608
New York, NY 10022
Re:Tonix Pharmaceuticals Holding Corp.
Registration Statement on Form S-1
Filed June 19, 2019
File No. 333-232195
Dear Mr. Lederman:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Sonia Bednarowski at 202-551-3666 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance